secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001104659-22-116477
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute Q1 FY2023 net loss $9.8M; cash $154.3M; RZ358/402 advance
------------------------------------------------------------------

- Cash and equivalents $154.3M as of Sep 30, 2022; net loss $9.8M vs $7.8M YoY.
- R&D expenses $7.7M (up 33% YoY); G&A $2.5M (up 32% YoY) on higher clinical and stock-based costs.
- RZ358 Phase 2b showed ~75% reduction in hypoglycemia events; regulatory discussions underway for Phase 3.
- RZ402 Phase 1b MAD data supports once-daily dosing; Phase 2 proof-of-concept study expected by end-2022.
- Closed $130M financing post-quarter to advance both molecules into next clinical stages.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465922116477/0001104659-22-116477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465922116477/tm2230110d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer